Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000585391 | SCV000693211 | likely pathogenic | not provided | 2017-09-01 | criteria provided, single submitter | clinical testing | |
Institute of Medical Genetics and Applied Genomics, |
RCV000585391 | SCV001447929 | likely pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001867900 | SCV002254557 | pathogenic | PRPH2-related disorder | 2024-09-08 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp316*) in the PRPH2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 31 amino acid(s) of the PRPH2 protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with adult vitelliform macular dystrophy (PMID: 9338584). ClinVar contains an entry for this variant (Variation ID: 493432). This variant disrupts a region of the PRPH2 protein in which other variant(s) (p.Val332Glu) have been determined to be pathogenic (PMID: 30718709, 32531846). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Leiden Open Variation Database | RCV000585391 | SCV001745201 | likely pathogenic | not provided | 2020-05-28 | no assertion criteria provided | curation | Curator: Global Variome, with Curator vacancy. Submitter to LOVD: IMGAG. |